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Abstract
Background: The importance of low high-density lipoprotein cholesterol (HDL-C), elevated non
HDL-C (as part of the metabolic syndrome, prediabetes, and type 2 diabetes mellitus), and an
isolated low HDL-C is rapidly emerging. The antiatherosclerotic roles of reverse cholesterol
transport and the pleiotropic antioxidant – anti-inflammatory mechanistic effects of HDL-C are
undergoing rapid exponential growth.
Case presentation: In 1997 a 53-year-old Caucasian male presented with a lipoprotein profile of
many years duration with an isolated low HDL-C and uric acid levels in the upper quintile of
normal. He developed an acute myocardial infarction involving the right coronary artery and had
percutaneous transluminal coronary angioplasty with stenting of this lesion. He also demonstrated
a non-critical non-flow limiting lesion of the proximal left anterior descending coronary artery at
the time of this evaluation.
Following a program of global risk reduction this patient has done well over the past 7 years and
remains free of any clinical signs and symptoms of atherosclerosis. His HDL-C and uric acid levels
are currently in the normal physiological range.
Conclusion:  Low HDL-C and isolated low HDL-C constitute an important risk factor for
atherosclerosis. Therapies that lead to a return to normal physiologic range of HDL-C may result
in the delay of atherosclerotic progression.
Case presentation
MRH, a 53-year-old Caucasian male (physician) devel-
oped an acute inferior myocardial infarction (MI) associ-
ated with bradycardia and occasional PVCs. Emergency
medication included aspirin, nitroglycerin and a bolus of
TPA.
The cardiology team preformed PCTA at the site of near
complete blockage of the right coronary artery with
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successful stent placement. At this time a non-critical 40%
lesion located in the proximal left anterior descending
coronary artery was noted, which was not manipulated.
The patient was discharged following 24 hours of stable
monitoring.
Past Medical History
Relapsing fever 1971 full recovery, spontaneous left pneu-
mothorax times two (1982–83), lumbar fusion back sur-
gery 1985, and Herpes Simplex encephalitis 1989 with full
recovery.
Family History
Mother with CVA (cerebellar) age 58 full recovery. Died of
Hodgkin's lymphoma 64. Brother with type 1 diabetes
mellitus with onset at age 29 (known PAD and aorto-fem-
oral bypass age 49) died in sleep age 51.
Father with CVA (vertebrobasilar) age 75 with full recov-
ery, COPD, died in sleep while recovering from TIA and
pneumonia age 84.
Grandparents lived to their 80s and died of old age.
Social History
High stress family physician who seldom drank alcohol
and smoked a pipe occasionally. Blood pressure at times
of high stress would elevate to 140/85–88 and return to
120–130s/ 70–75 at times of non-stress in the office. He
was physically active with no dedicated exercise program
Laboratory Values
Five months prior to MI and reflective of numerous meta-
bolic profiles over the preceding decades.
Total cholesterol 198 mg/dL
Triglycerides 154 mg/dL
HDL-C 34 mg/dL. HDL-C (1970–1973 32 mg/dL and 34
mg/dL)
LDL-C calculated 120 mg/dL
Non HDL-C = (198-34) = 164
Total Chol/HDL ratio = 6.2 > than 5 and is high
Uric acid 6.5 mg/dL
Blood sugar non-fasting 102 mg/dL
Homocysteine first week post MI fasting: 28 mcmol/L
LFTs, electrolytes, calcium and phosphorus, serum
iron, renal function, and CBC were all in normal range.
Patient started a program reflecting the global risk reduc-
tion approach described in the RAAS acronym (table 1)
and is currently taking an angiotensin receptor blocker,
aspirin, beta blocker, folic acid, and a statin. Patient was
intolerant of ACE inhibitor therapy due to cough and
fatigue and has been unable to tolerate niacin on numer-
ous attempts both pre and post MI due to incapacitating
headaches.
Current Laboratory Values 2004:
Total cholesterol: 138 mg/dL
Triglycerides: 94 mg/dL
HDL-C: 45 mg/dL
LDL-C calculated: 74 mg/dL
Non HDL-C: (138-45) = 93
Total Chol/HDL ratio = 3.0
Uric acid: 6.5 mg/dL
Blood sugar: Fasting 80 mg/dL, 2 hour post prandial
118 mg/dL
Homocysteine: 7.2 mcmol/L
Lp(a): 4.2 mg/dL in normal range immediate post MI
and again at this time: 4.3 mg/dL.
hs-CRP: 0.7 mg/L.
LFTs, electrolytes, calcium and phosphorus, serum
iron, renal function, and CBC are all in normal range.
This patient has done well over the past seven years and
remains free of any clinical signs and symptoms of cardi-
ovascular disease. While this patient will always remain a
CHD risk, his current laboratory values remain in a nor-
mal physiological range. As noted above his HDL-C and
uric acid levels are currently in the normal physiological
range and his hs-CRP remains in the second quartile.
Comment
According to Framingham risk scores associated with the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) guidelines [1], few would have
recommended any treatments other than therapeuticCardiovascular Diabetology 2005, 4:1 http://www.cardiab.com/content/4/1/1
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lifestyle changes (TLC) and possibly niacin, which our
patient was intolerant both pre and post event in 1997.
If we score this patient according to the estimate of 10-
year risk for men he gets 6 points for age 53, 2 points for
total cholesterol 160–199 age 53, 3 points for being a pipe
smoker, 2 points for HDL being < 40 mg/dL, and 1 point
for systolic blood pressure 140–159 untreated. This totals
14 points and results in an estimated 10-year risk for men
of 16%, which is less than the 20% recommended for
more aggressive therapy.
Even if we apply the NCEP ATP III guidelines of having
two plus risk factors: Male sex, hypertension, smoking,
and low HDL-C with a 10 risk < or = to 20% we obtain the
following recommendations: LDL-C goal < 130 mg/dL,
initiation of TLC if LDL-C is = or > 130 mg/dL, considera-
tion of drug therapy if LDL-C is > or = to 130 mg/dL after
three months of TLC. It is important to note that our
patient had a LDL-C of 120 mg/dL prior to his event. Even
if we look at the non HDL-C levels, which are allowed to
be 30 mg/dL higher than LDL-C goals we have a patient
with a non HDL-C of only 164. MRH became a CHD risk
patient within a short period of time of 5 months.
Discussion
The importance of low HDL-C and cardiovascular disease
associated with the lipid triad (Low HDL-C, elevated trig-
lycerides, and increased small dense LDL-C) found in the
metabolic syndrome (metS) and overt type 2 diabetes
mellitus (T2DM) and a contributing factor to the elevated
non HDL-C discussed in the current NCEP ATP III guide-
lines or the patients with isolated low HDL-C is rapidly
evolving.
The accelerated atherosclerosis (atheroscleropathy) asso-
ciated with the metS and T2DM has been previously
reviewed and is definitely a serious problem associated
with the current epidemic of obesity – diabesity and
T2DM [2-4].
Table 1: The RAAS acronym: global risk reduction
R Reductase inhibitors (HMG-CoA). Decreasing modified LDL-cholesterol, i.e. oxidized, acetylated LDL-cholesterol. Decreasing 
triglycerides and increasing HDL-cholesterol Improving endothelial cell dysfunction. Restoring the abnormal Lipoprotein fractions. Thus, 
decreasing the redox and oxidative stress to the arterial vessel wall and myocardium.
Redox stress reduction.
A AngII inhibition or blockade:
ACEi-prils. ARBS-sartans. Both inhibiting the effect of angiotensin-II locally as well as systemically. Affecting hemodynamic stress through 
their antihypertensive effect as well as the deleterious effects of angiotensin II on cells at the local level – injurious stimuli -decreasing the 
stimulus for O2. production. Decreasing the A-FLIGHT toxicities. Plus the direct-indirect antioxidant effect within the arterial vessel wall 
and capillary. Antioxidant effects.
Aspirin antiplatelet, anti-inflammatory effect.
Adrenergic (non-selective blockade) in addition to its blockade of Prorenin→Renin
Amlodipine with its calcium channel blocking antihypertensive effect, in addition to its direct antioxidant effects.
Redox stress reduction.
A Aggressive control of diabetes to HbA1c of less than 7. (This usually requires combination therapy with the use of: Insulin secretagogues, 
insulin sensitizers (thiazolidinediones), biguanides, alpha-glucosidase inhibitors, and ultimately exogenous insulin.) Decreasing modified LDL 
cholesterol, i.e. glycated – glycoxidated LDL cholesterol. Improving endothelial cell dysfunction. Also decreasing glucotoxicity and the 
oxidative – redox stress to the intima and pancreatic islet.
Aggressive control of blood pressure, which usually requires combination therapy, including thiazide diuretics to attain JNC 7 
guidelines.
Aggressive control of dyslipidemias, which frequently requires combination therapy (especially in the metabolic syndrome and T2DM), 
including TLC, statins, fibrates, selective cholesterol inhibitors such as ezetimibe, and niacin
Aggressive control of Hcy with folic acid with its associated additional positive effect on re-coupling the eNOS reaction by restoring the 
activity of the BH4 cofactor to run the eNOS reaction and once again produce eNO.
Redox stress reduction.
SS t a t i n s .   Improving plaque stability (pleiotropic effects) independent of cholesterol lowering. Improving endothelial cell dysfunction. Plus, the 
direct – indirect antioxidant anti-inflammatory effects within the islet and the arterial vessel wall promoting stabilization of the unstable, 
vulnerable islet and the arterial vessel wall. Style: Lifestyle modification: lose weight, exercise, and change eating habits. Stop Smoking
Redox stress reduction
Table 2: Effects of drugs on HDL-C levels
DRUG PERCENT 
INCRESE
Nicotinic acid (niacin) 15% – 35%
Fibrates 10% – 15%
Estrogens 10% – 15%
Statins
Coupled Dual Effect
Associated with potent LDL-C reduction, which 
make the statins "shine"
5% – 10%
Alpha blockers 10% – 20%
Alcohol (in moderation) 10%
Ezetimibe 3%Cardiovascular Diabetology 2005, 4:1 http://www.cardiab.com/content/4/1/1
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Both isolated low HDL-C and elevated non HDL-C (total
cholesterol minus HDL-C) levels are difficult to get to
known NCEP ATP III recommendations and this task usu-
ally requires combination therapy. These therapies consist
of therapeutic life style changes and pharmacotherapy
including statins, fibrates, selective cholesterol inhibitors
such as ezetimibe, and niacin in addition to a global risk
reduction of all non HDL-C existing risk factors (table 2)
[5].
In this case report a focus on isolated low HDL-C is appro-
priate. This case report demonstrates a marked improve-
ment of all lipid parameters including his low HDL-C.
However, this marked improvement is not always as sim-
ple as this case and therefore, both the patient and the cli-
nician need to be very patient, as well as, creative in order
to achieve global risk reduction [5].
Isolated low HDL-C
In 1977 the Tromso Heart Study demonstrated that CAD
patients have HDL-C levels 35% lower than controls and
those patients with low HDL-C are three times more likely
to develop CAD than those with elevated LDL-C [6]. These
early views certainly support the concept that an isolated
low HDL-C is a common antecedent of clinical CHD, as
well as being important in accelerating the progression of
atherosclerosis.
The inverse relation of HDL-C to CHD events has been
widely discussed since the original publication of data
from the Framingham study (1986) [7,8]. Castelli WP et
al. were able to show an inverse association of high HDL-
C and low coronary risk was as statically as strong as the
direct association of high LDL-C and high coronary risk in
a cohort of men and women age 40–82 followed for 12
years who were free from CAD at study entry. At any level
of cholesterol low HDL-C increases the rate of CHD [1]
The NCEP ATP III guidelines clearly defines a level < 40
mg/dL as an independent risk factor for CHD [1]. Raising
HDL-C is not a target for either primary or secondary pre-
vention at this time, however its importance as a tertiary
target is rapidly emerging.
Michael Miller has stated: "Low HDL-C is the most com-
mon lipoprotein abnormality in patients with CHD and is
predictive of CHD events, even when total cholesterol lev-
els are normal" [9].
Goldbourt U et al., found that the prevalence of isolated
low HDL-C as a risk factor for CHD mortality to be
present in one out of six or 16.6 % while studying a 21-
year follow up of 8000 men [10]. Furthermore, they
found that an excess CHD risk associated with isolated
low HDL-C appeared particularly increased in men with
diabetes mellitus, whose death rate was 65% higher than
in diabetics with HDL-C > 0.9 mmol/L or 36 mg/dL.
There are at least eight secondary causes for low HDL-C
(table 3) and at least seven drugs that have a positive effect
on raising HDL-C (table 2). As demonstrated in our case
report, the beneficial effects of raising HDL-C with statin
therapy and a program of global risk reduction have been
positive in preventing the progression of atherosclerosis
and recurrent acute coronary syndromes (table 4).
HDL-C is synthesized in the intestine and liver and is
extremely important in reverse cholesterol transport from
the tissues to the liver for disposal. It works in conjunction
with the ABCA1 cholesterol transporter within the intimal
macrophages (figure 1).
This important dual interaction of HDL-C and the ABCA1
transporter is of great importance and recently we have
learned that certain gene polymorphism of ABCA1 trans-
porter may have a profound effect on HDL-C in addition
to the well known abnormality of Tangier disease [11].
Table 3: Secondary causes of low HDL-C
1. Elevated triglycerides. (Component of metS)
End stage renal disease
Hypothyroidism [also increased total Chol/HDL-C ratio.
2. Obesity and Overweight. – [waist measurement] – (Component of metS)
[Visceral obesity in particular]
For every 3 kg. (7 lbs.) weight loss HDL-C increased 1 mg/dL.
3. Prediabetes and overt Type 2 Diabetes Mellitus. (Component of metS)
4. Physical inactivity (lifestyle choice).
5. Smoking (lifestyle choice).
6. Very high carbohydrate intakes > 50–60% of energy (lifestyle choice).
[Especially Fructose Containing Soft Drinks.]
7. Metabolic Syndrome: As potent a risk factor as smoking.
8. Drugs, such as beta-blockers, anabolic steroids, and progestational agents.Cardiovascular Diabetology 2005, 4:1 http://www.cardiab.com/content/4/1/1
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Probst MC et al., have even set aside a website to list all of
the known ABCA1 gene polymorphisms [11].
Oxidative stress and the reductive stress (redox stress)
associated with overt T2DM and multiple risk factors asso-
ciated with accelerated atherosclerosis may result in a
damaging effect to HDL-C and interfere with the ABCA1
transporter in reverse cholesterol transport via a mecha-
nism of oxidation and nitration of tyrosine residues on
the apo A-1 lipoprotein outer shell of HDL-C lipoprotein
[12]. This biochemical alteration of the apo A-1 lipopro-
tein could disable the process of reverse cholesterol trans-
port and aggravate an underlying isolated low HDL-C
level.
Lifestyle changes that are important in raising low HDL-C
consist of smoking cessation, weight loss, exercise, and the
use of alcohol in moderation.
HDL-C has numerous positive effects on the endothelium
and arterial vessel wall, which decrease non-diabetic
atherosclerosis and the accelerated atherosclerosis –
atheroscleropathy associated with metS and overt T2DM
(table 4).
Emerging novel risk markers of atherosclerosis
NCEP ATP III allows the clinician to factor in the addi-
tional risks associated with novel, emerging risk markers
such as our patients elevated homocysteine. Other risk
markers would be the lipid markers: Elevated triglyceride,
remnant lipoproteins, lipoprotein (a), an abnormal TC/
HDL-C ratio, small dense LDL particles, HDL subspecies,
and apolipoprotein A and B. The non lipid markers would
include: An elevated glucose, inflammatory markers (ele-
vated hs-CRP and the emerging importance of the various
interleukins and in particular IL-6, which is the driving
force behind hs-CRP elevation), coagulation markers (ele-
vated PAI-1, Lp(a), and fibrinogen), the emerging roles of
matrix metalloproteinases (MMPs) and of course the
established risk marker of an elevated homocysteine. It is
interesting to note that Qujeq D et al., noted a negative
correlation between total homocysteine and HDL-C levels
(p < 0.05, r = 0.93) in a study evaluating 126 patients (67
male and 59 females, aged 29–73 mean of 48.65 +/- 5.79)
with unequivocal changes of acute myocardial infarction
in the electrocardiogram as compared to 135 normal
healthy controls, while noting a positive correlation
between total homocysteine and LDL-C levels (p < 0.05, r
= 0.98) [13]
The reader may note that the patients' uric acid level was
quite elevated prior to his acute coronary event and that
this level returned to a very normal level following global
risk reduction and aggressive therapy for his multiple risk
factors in addition to his isolated low HDL-C. Although
not a considered a risk factor or even an emerging, novel
risk marker, uric acid may be a quite sensitive marker of
underlying redox and oxidative stress. Uric acid levels
greater than 4 mg/dL may be considered a red flag in those
patients, such as our case report, with high risk for CHD
[14].
The Atherosclerotic Kitchen Sink
When viewing the sources for atherosclerosis it is impor-
tant to note that there are two routes for accumulation of
atherogenic lipoproteins (input and outflow) within the
arterial intima and subsequent remodeling of the arterial
vessel wall.
The atherosclerosis equation: Lipoprotein Accumulation
(retention) in the arterial vessel wall = Lipoprotein in -
lipoprotein out. L-A avw = L-in - L-out.
L-in, would equal the net lipoproteins derived from the GI
tract (absorption) plus that synthesized by the liver. Lipo-
protein out is strictly via reverse cholesterol transport to
the liver and secretion via bile into the gut. L-in is prima-
rily the beta lipoproteins or apolipoprotein B containing
lipoprotein particles, whereas L-out depends primarily on
the alpha lipoproteins, apolipoprotein A or HDL-C. The
beta lipoproteins are atherogenic and the alpha lipopro-
teins are antiatherogenic. From this analogy one can see
can see why non HDL-C was so important in the recent
NCEP ATPIII guidelines: non HDL-C = total Cholesterol
– HDL-C (reflecting the total atherogenic burden).
Table 4: Beneficial effects of HDL-C
REVERSE CHOLESTEROL TRANSPORT
Accepts cholesterol from the macrophage and tissues and transports 
it back to the liver for disposal in the bile (figure 1).
Acts a an apoprotein donor to the other lipoproteins
ANTIOXIDANT
Antioxidant activity (through intimal paraoxonase, and redox -
sensitive methionine residues of apo A-1)
Increases eNOS and endothelial nitric oxide
ANTIINFLAMMATORY
Downregulates adhesion molecule expression on endothelium: (I-
CAM, V-CAM and MCP-1)
Inhibits neutrophil degranulation
ANTITHROMBOTIC
Antithrombotic activity via its ability to block TxA2 and potentiates 
activity of proteins: C and S.
Stimulates prostacyclin production (antithrombotic and vasodilitory).
ENDOTHELIAL PROTECTION PROTERTIES
Acts as an endothelial mitogen and inhibits endothelial cell apoptosis: 
This would help to decrease the incidence of plaque erosion and 
promote plaque stabilization
Stimulates endothelial nitric oxide (eNO and its enzyme eNOS) and 
prostacyclin production with vasodilatation, antioxidant, and anti-
inflammatory properties.Cardiovascular Diabetology 2005, 4:1 http://www.cardiab.com/content/4/1/1
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This is also why the recent global (52 countries) INTER-
HART study found the ApoB/ApoA-1 ratio (the ratio of
atherogenic lipoproteins to non atherogenic lipoproteins)
to be the best predictor of CHD (odds ratio of 3.25 for top
verses lowest quintile) as compared to the other eight
other risk factors (table 5) [15].
L-Aavw = ApoB/ApoA-1 ratio of the INTERHART study
L-in, would be comparable to the faucet (GI tract and
Liver) delivering the atherogenic apoB lipoproteins. While
the kitchen sink would represent the accumulation of
atherogenic lipoproteins within the arterial vessel wall or
L-Aavw.
Reverse Cholesterol Transport Figure 1
Reverse Cholesterol Transport. This figure demonstrates the process of reverse cholesterol transport. It begins in the 
arterial vessel wall and with the assistance of the ATP binding cassette transporter A-1 (ABCA-1) and in collaboration with the 
Apo A-1 protein attached to the outer shell of the nascent HDL-C lipoprotein particle free cholesterol is internalized within 
the HDL-C lipoprotein particle. The enzyme lecithin cholesterol acyltransferase (LCAT) esterifies free cholesterol (FC) via a 
lipidation process and internalizes it within the HDL-3, which matures to a larger HDL-2 lipoprotein particle. From this point 
in time the HDL-3 and 2 particles can enter the hepatic cycle via the Scavenger Receptor B-1 and subsequently excreted in the 
bile. The alternative pathway is for the larger HDL-C apoA-1 lipoprotein particles to undergo a transference of the cholesterol 
esters through an exchange process with triglycerides via cholesterol ester transfer protein (CETP) to the ApoB-100 lipopro-
tein particles and enter the liver for further metabolism via the low density lipoprotein receptor (LDLR) to be subsequently 
excreted in the bile.
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In a like manner, the DRAIN would represent L-out or
HDL-C or apoA-1 lipoproteins. From this analogy it can
easily be seen that if there is inadequate HDL-C or apoA-
1 the atherogenic kitchen sink will overflow and result in
acute coronary syndromes as happened in our case report
(figure 2).
Conclusion
While the treatment of isolated HDL-C may seem over-
whelming at times, it will be rewarding for both the clini-
cian and the patient as demonstrated by the our case
study. This patient has done well for seven years and it is
anticipated he will continue to do well with his laboratory
values now in a sustained, normal physiologic range.
Additional tests by nuclear magnetic resonance spectros-
copy (NMR LipoProfile) would assist us in knowing the
LDL particle number (LDL-P) and would assist us in even
more aggressive therapy. In addition to his current goals
he has met, he should have an LDL-P under 1000 micro-
mol/L and small LDL-P under 700 micromol/L.
Even though we have discussed LDL-C from a quantity
perspective, due to an isolated low HDL-C, we should
additionally be aware that there exists and equally impor-
tant role for the quality of HDL-C [12]. Recently, the Apo
A-1Milano  and  Apo A-1Paris  have resulted in a marked
increase in research interest for the HDL-C lipoprotein
particle and its future manipulation [16]. In the near
future we may be utilizing gene transfer utilizing varia-
tions of the Milano and Paris forms, as well as the newer
apoA-1 mimetics such as L-4F [17]. Recently there has
been increased interest in CETP inhibitors and Phase II
studies are underway with torcetrapib and the combina-
tion of torcetrapib and atorvastatin [18]. Additional atten-
tion to the PPAR agonists and atherosclerosis and the liver
X receptor alpha (LXR alpha) agonists is being employed
at the present and the positive dual effects on HDL-C and
atherosclerosis is being actively investigated. This dual
agonism of PPAR alpha, gamma, and possible delta, as
well as the dual effects of PPAR alpha and LXR alpha are
quite exciting and we will learn a great deal regarding their
effects on atherosclerosis and HDL-C in the near future
[19].
Recently John Snow, M.D. (1813–1858), a legendary fig-
ure in the field of epidemiology, of London, England was
honored [20]. He hypothesized that Cholera was trans-
mitted by water rather than miasma (bad air). He sus-
pected the water from the Broad Street pump was the
source of the disease and subsequently had the pump
handle removed in 1854 (150 years ago) [21].
Could low HDL-C be the "pump handle" of atherosclero-
sis and CHD?
List of abbreviations
ABCA-1: ATP binding cassette transporter A-1
BMI: body mass index
CHD: coronary heart disease
CAD: coronary artery disease
hs-CRP: highly sensitive C reactive protein
T2DM: type 2 diabetes mellitus
metS: metabolic syndrome
HDL-C: high density lipoprotein cholesterol
LDL-C: low density lipoprotein cholesterol
LFTs: liver function tests
PCTA: percutaneous transluminal coronary angioplasty
Table 5: Nine risk factors account for up to 90 % of MIS worldwide in both sexes, all ages, and in all regions
RISK FACTOR ODDS RATIO
Abnormal lipids: ApoB/ApoA-1 3.25
Smoking 2.87
Diabetes 2.37
Hypertension 1.91
Abdominal obesity
Reason for such a high OR: This could aggravate smoking, diabetes, hypertension, obesity, alcohol 
abuse and even nutrition (eating aggressively)
1.12
Psychosocial Factors 2.67
Alcohol use 0.91
Physical Activity 0.86
Consumption of fruits and vegetables 0.70Cardiovascular Diabetology 2005, 4:1 http://www.cardiab.com/content/4/1/1
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VLDL-C: very low density lipoprotein cholesterol
TC: total cholesterol
TLC: therapeutic lifestyle changes
TPA: tissue plasminogen activator
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The Atherosclerotic Kitchen Sink Figure 2
The Atherosclerotic Kitchen Sink. This image portrays the importance of the HDL-C drain in maintaining a certain level 
of atherogenic lipoproteins within the arterial vessel wall to prevent accumulation and the undesirable possibility of an acute 
event with overflow or acute coronary syndromes. This simple analogy of homeostasis points to an important concept: That 
being the frequent need for combination therapy in order to control the various components of the atherogenic lipoprofile. 
Isolated low HDL-C is certainly a red flag regarding the development of atherosclerosis and CHD and additionally the elevation 
of low HDL-C levels may have a DRANO-LIKE effect to open a clogged drain in an atherosclerotic arterial vessel wall.
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